Johnson Anne Nagengast 的 Form 4 申報
AtaiBeckley Inc.（ATAI），2026/9/11 申報
- 申報編號
- 0001140361-26-036388
- 申報時間
- 2026/9/11 17:44 ET
- 交易日
- 2026/9/11
- 申報延遲
- 當天
- 10b5-1 計畫
- 沒有勾選
這份申報列了 1 筆非衍生性交易、8 筆衍生性交易。交易當天就申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Johnson Anne NagengastCIK 0001976640 | 高階主管（會計主管） |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/9/11 | Common Stock | D交回公司處分 | −326,416 | –F3 | – | 0 | 直接 | |
| 2026/9/11 | Common Stock | D交回公司處分 | −200,000 | –F3 | – | 0 | 直接 | |
| 2026/9/11 | Common Stock | D交回公司處分 | −71,620 | –F3 | – | 0 | 直接 | |
| 2026/9/11 | Common Stock | D交回公司處分 | −500,000 | –F3 | – | 0 | 直接 | |
| 2026/9/11 | Common Stock | D交回公司處分 | −550,000 | –F3 | – | 0 | 直接 | |
| 2026/9/11 | Common Stock | D交回公司處分 | −757,915 | –F3 | – | 0 | 直接 | |
| 2026/9/11 | Common Stock | D交回公司處分 | −525,000 | –F3 | – | 0 | 直接 | |
| 2026/9/11 | Common Stock | D交回公司處分 | −117,000 | –F4 | – | 0 | 直接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent.
表 I 有 1 筆交易的價格引用這則附註。
- F2
At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, converted into the right to receive (i) $6.75 per share in cash, without interest, plus (ii) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding.
表 I 有 1 筆交易的價格引用這則附註。
- F3
At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).
表 II 有 7 筆交易的價格引用這則附註。
- F4
At the Effective Time, each outstanding restricted stock unit ("RSU"), subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such RSU immediately prior to the Effective Time multiplied by (2) $6.75 and (B) one CVR for each share subject to such RSU immediately prior to the Effective Time (without regard to vesting).
表 II 有 1 筆交易的價格引用這則附註。